← All trials
NCT04866017
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 17, 2021
- Primary completion
- Jan 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Apr 29, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 900
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BeOne MedicinesLead sponsor
- BeOne MedicinesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.